BiotechTube

SHR6390 + placebo

Phase 3Active
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer

Conditions

Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer

Trial Timeline

Apr 30, 2021 → Oct 31, 2031

NCT ID
NCT04842617

About SHR6390 + placebo

SHR6390 + placebo is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04842617. Target conditions include Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04842617Phase 3Active

Competing Products

20 competing products in Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer

See all competitors
ProductCompanyStageHype Score
SomatropinEli LillyPhase 3
77
Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)Eli LillyPre-clinical
23
Datopotamab Deruxtecan (Dato-DXd) + Steroid Containing MouthwashDaiichi SankyoPhase 1
33
Enzalutamide + Placebo + Androgen deprivation therapy (ADT)Astellas PharmaPhase 3
77
EnzalutamideAstellas PharmaPhase 2
52
Enzalutamide + Placebo (No longer applicable in Open Label study period) + Leuprolide Open LabelAstellas PharmaPhase 3
77
Enzalutamide + PlaceboAstellas PharmaPhase 3
77
YM598Astellas PharmaPhase 2
52
pegylated Somatropin + pegylated Somatropin + Jintropin AQSun PharmaceuticalPhase 2
52
PEG-somatropinSun PharmaceuticalApproved
85
PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved
85
PEG-somatropinSun PharmaceuticalPhase 3
77
ONO-4578 + letrozole + Palbociclib + abemaciclibOno PharmaceuticalPhase 1
33
Somatropin + SomatropinEli LillyPhase 3
77
Abemaciclib + Trastuzumab + Fulvestrant + Standard of Care Single Agent ChemotherapyEli LillyPhase 2
52
Somatropin + SomatropinEli LillyPhase 3
77
Abemaciclib + Aromatase Inhibitor + Abemaciclib + FulvestrantEli LillyApproved
85
dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets + placebo; abiraterone acetate tablets; prednisone tabletsJiangsu Hengrui MedicinePhase 1
33
SHR7280 tablets + SHR7280 dry suspensionJiangsu Hengrui MedicinePhase 1
33
SHR7280Jiangsu Hengrui MedicinePhase 1
33

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85